News
Company News: akampion’s Clients Featured in Major Trade and Economics Media
akampion has successfully positioned its clients in various international trade and economics media during the last weeks.
Among others, Surgical Process Institute, a provider of all-in-one solutions for surgery-focused clinics, has been introduced in a four-page article in Wirtschaftswoche 47 (Nov. 19, 2012). Wirtschaftswoche is the world’s largest German-language economics magazine with a circulation of >173,000 copies, reaching 0.9 million readers.
bubbles & beyond, which is developing intelligent fluids for a variety of industrial and other applications, has been introduced in a two-page article in brand eins (12/2012), Germany’s most prestigiuos monthly economics magazine (circulation of nearly 110,000 copies).
European Hospital (Vol. 21, Issue 5/12) in November reported on the collaboration of molecular diagnostics company Curetis AG with Heraeus Medical to develop a novel Unyvero(TM) cartridge to detect pathogens and antibiotic resistances in implant and tissue infections (ITT). The same issue is introducing French company Nanobiotix SA which is developing a revolutionary new approach for cancer radiotherapy. The company went public in France earlier this month. European Hospital has a circulation of 30,000 copies and is read widely across Europe (majority of copies sold in Germany, UK, France, Russia, Spain, Italy) – mostly by hospital managers and chief physicians.
L’Agefi, Switzerland’s leading business and financial newspaper (readership: 115,000), on November 7 reported on the start of a European Phase IIb trial of the company’s birch pollen allergy vaccine. The news was also picked up by BioWorld and BioCentury.
Company News: Long-Term Immunomodulation Induced by Anergis´ COP Allergy Vaccine AllerT Now Extends to the 4th Year After Treatment
Patients with birch pollen allergy who received an ultra-fast allergy vaccine four years ago maintain an elevated level of antibodies against the allergen, reports Swiss biopharmaceutical company Anergis.
The company, which is developing breakthrough allergy vaccines for fast and safe allergen-specific immunotherapy, today announced new data on the immune-regulatory effect of its AllerT vaccine.
In 2008/2009, twenty patients suffering from moderate to severe allergies to birch pollen were enrolled in a double-blind, randomized, placebo-controlled Phase I/IIa trial and received 5 subcutaneous injections over 2 months of either AllerT (N=15) or placebo (N=5). Four years later, all subjects were invited to return to the trial center. In subjects who had received AllerT, blood levels of so-called IgG4 antibodies against specific birch pollen allergens were similar to those reported after 2 years (in 2010) and still 4.5 times higher than the pre-treatment baseline level (p< 0.001). Placebo-treated patients showed no median change from baseline in allergen-specific IgG4 at any time during the trial treatment period, nor after the 2010 and 2012 birch pollen seasons.
Earlier this week, Anergis also announced the start of a large, 300-patient real-life seasonal efficacy phase IIb trial with AllerT in patients allergic to birch pollen. This trial is being conducted in multiple European countries [NCT01720251].
Company News: Anergis Starts European Phase IIb Clinical Trial with AllerT in Patients with Moderate to Severe Allergy to Birch Pollen
– First patient treated with novel allergy vaccine –
Anergis, a company developing breakthrough allergy vaccines for fast and safe allergen-specific immunotherapy, reported today that it has treated the first patient in a large, well-controlled Phase IIb clinical trial in individuals with birch pollen allergy. The trial is designed to evaluate the efficacy and tolerability of a 5-injection / 2- months treatment with Anergis´ lead allergy vaccine, AllerT.
The multicentre, double-blind, placebo-controlled, randomized trial called AN004T was designed in collaboration with an International Steering Committee of experts with comprehensive experience in the design and conduct of allergen-specific immunotherapy trials(1). The trial will enroll about 300 patients with moderate to severe birch pollen allergy from up to 30 trial centers throughout Europe. Trial centers are located in Denmark, France, Latvia, Lithuania, Poland, Sweden and Switzerland. AN004T will evaluate the efficacy and safety of two doses of AllerT in comparison with placebo. The first patient was randomized and treated on November 3rd, 2012, in Vilnius, Lithuania.
As recommended by the European Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases (CHMP/EWP/18504/2006), the efficacy of AllerT will be assessed using a combined symptom and medication score as primary endpoint of the trial (combined Rhinoconjunctivitis Symptom and Medication Score RSMS). RSMS assessment is based on allergy symptom and medication data reported through electronic diaries by the trial subjects during the 2013 birch pollen season. Secondary and exploratory endpoints will include other clinical parameters related to symptoms and/or medications taken for allergy, as well as quality of life and immunological marker assessments.
Company News: Meet akampion at BIO-Europe 2012 in Hamburg
akampion´s management team is going to attend BIO-Europe in Hamburg (November 12-14, 2012). In addition to supporting clients with their IR/PR activities during the conference, we will be available for meetings. If you are interested to learn more about akampion or would like to give us an update on your company´s progress, we will be happy to meet you! You can either request meetings via partneringONE, EBD Group´s leading-edge online partnering system, or send us an email: info(at)akampion.com. We are looking forward to talking to you!